EUVIMEDEUVIMED entdecken
Multizentrische Studie

Risk Factors for Pituitary Adenoma Development in Multiple Endocrine Neoplasia Type 1: A Nationwide Study of 240 Cases

Nuria Valdés iD, Ana R Romero-Lluch, Estrella Diego, María Calatayud, Cristina Lamas iD, Marta Araujo-Castro, Rosa Martínez iD, Josep Oriola, Cristina Álvarez-Escolá, Ángel Díaz Pérez, Victoria Alcázar, Julia Sastre und 7 weitere

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgaf497 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Nuria Valdés und 18 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology & Nutrition Department, Hospital Universitario Cruces, 48903 Barakaldo, Bizkaia, Spain. Hauptthemen laut MEDLINE: Multiple Endocrine Neoplasia Type 1, Pituitary Neoplasms, Adenoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Pituitary adenomas (PAs) are one of the three major lesions in Multiple Endocrine Neoplasia type 1 (MEN1), with a prevalence of 32% to 58%, yet their specific risk factors remain unidentified. This study aimed to identify predictors influencing PA occurrence in MEN1.

Methods

This nationwide, multicenter, retrospective cohort study involved 240 MEN1 patients, 55.8% female. The main variables were age-related penetrance, PA subtype and size, and MEN1 germline pathogenic variants (PVs). The primary outcome was PA development. Cox regression was applied first to the full cohort and then to a prospectively screened subgroup (n = 199) free of symptom-driven bias.

Results

PAs were detected in 112 (46.6%) patients at a mean age of 36.1 ± 13.9 years; most (63.3%) were diagnosed through screening. Prolactinomas (49.1%) and microadenomas (62.5%) predominated. In the full cohort, the following independent factors were related to PA development: age (per additional year; HR 0.916, 95% CI 0.893-0.993; P < .001), prior primary hyperparathyroidism (HR: 3.090, 95% CI: 1.943-4.914, P < .001), non-missense MEN1 PVs (HR: 1.976, 95% CI: 1.125-3.468, P = .018), and female sex (HR: 1.706, 95% CI: 1.082-2.689, P = .022). The same factors remained significant in the screened subgroup.

Conclusion

Risk of PA in MEN1 clusters at younger ages and declines thereafter. Prior primary hyperparathyroidism, non-missense MEN1 PVs, and female sex further mark higher-risk profiles. These findings may help personalize PA follow-up—prioritizing closer imaging in early adulthood and allowing longer intervals when baseline imaging is normal and additional risk markers are absent—pending validation in larger multicenter studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple Endocrine Neoplasia Type 1Pituitary NeoplasmsAdenomaHumansFemaleMaleAdultRisk FactorsMiddle AgedRetrospective StudiesYoung AdultAdolescentGerm-Line MutationAgedProto-Oncogene Proteins

Stichwörter der Autor:innen

MEN1genotype-phenotype correlationnon-functioning pituitary adenomaspituitary adenomasprolactinomas

Substanzen

MEN1 protein, humanProto-Oncogene Proteins

Autor:innen und Institutionen

  • Endocrinology & Nutrition Department, Hospital Universitario Cruces, 48903 Barakaldo, Bizkaia, Spain.
  • Biobizkaia Health Research Institute, Hospital Universitario Cruces, University of the Basque Country (UPV/EHU), CIBERDEM, CIBERER, Endo-ERN, 48903 Barakaldo, Bizkaia, Spain.
  • Endocrinology & Nutrition Department, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain.
  • Endocrinology & Nutrition Department, Hospital Universitario Cruces, 48903 Barakaldo, Spain.
  • Endocrinology & Nutrition Department, Hospital Universitario Doce de Octubre, 28041 Madrid, Spain.
  • Endocrinology & Nutrition Department, Complejo Hospitalario Universitario de Albacete, 02006 Albacete, Spain.

ORCID-Profile: Nuria Valdés, Cristina Lamas, Rosa Martínez

Zitieren

APA

Valdés, N., Romero-Lluch, A. R., Diego, E., Calatayud, M., Lamas, C., Araujo-Castro, M., Martínez, R., Oriola, J., Álvarez-Escolá, C., Pérez, Á. D., Alcázar, V., Sastre, J., Del Olmo, M. I., Boix, E., Vicente, A., Garcia-Centeno, R., Pérez-Fernández, S., Chiara, M. D., & Casterás, A. (2026). Risk Factors for Pituitary Adenoma Development in Multiple Endocrine Neoplasia Type 1: A Nationwide Study of 240 Cases. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf497

Vancouver

Valdés N, Romero-Lluch AR, Diego E, Calatayud M, Lamas C, Araujo-Castro M, et al. Risk Factors for Pituitary Adenoma Development in Multiple Endocrine Neoplasia Type 1: A Nationwide Study of 240 Cases. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgaf497

BibTeX
@article{Valds2026,
  author = {Valdés, Nuria and Romero-Lluch, Ana R and Diego, Estrella and Calatayud, María and Lamas, Cristina and Araujo-Castro, Marta and Martínez, Rosa and Oriola, Josep and Álvarez-Escolá, Cristina and Pérez, Ángel Díaz and Alcázar, Victoria and Sastre, Julia and Del Olmo, María Isabel and Boix, Evangelina and Vicente, Almudena and Garcia-Centeno, Rogelio and Pérez-Fernández, Silvia and Chiara, María Dolores and Casterás, Anna},
  title = {Risk Factors for Pituitary Adenoma Development in Multiple Endocrine Neoplasia Type 1: A Nationwide Study of 240 Cases},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgaf497}
}
Kostenlos starten →